Effect of Clinicopathological Characteristics on the Outcomes of Topical 5-Aminolevulinic Acid Photodynamic Therapy in Patients with Cervical High-Grade Squamous Intraepithelial Lesions (HSIL/CIN2): A Retrospective Cohort Study
by
,
Yingting Wei
1,2,†
,
Jing Niu
1,2,†,
Liying Gu
1,2,
Zubei Hong
1,2,
Zhouzhou Bao
1,2,3,* and
Lihua Qiu
1,2,3,* 1
Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
2
Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
3
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomedicines 2024, 12(10), 2255; https://doi.org/10.3390/biomedicines12102255
Submission received: 26 August 2024
/
Revised: 15 September 2024
/
Accepted: 25 September 2024
/
Published: 3 October 2024
(This article belongs to the Special Issue Photodynamic Therapy (3rd Edition))
Abstract
:Background: Minimally-invasive 5-aminolevulinic acid photodynamic therapy (ALA-PDT) is used for treating cervical high-grade squamous intraepithelial lesions (HSIL/CIN2). The purpose of this study was to analyze the factors affecting the efficacy of ALA-PDT in the treatment of cervical HSIL/CIN2 in order to guide physicians in making appropriate treatment decisions. Methods: A retrospective study including 69 female patients with pathologically diagnosed HSIL/CIN2 was conducted. Patients were given six doses of 20% ALA-PDT at 7–14-day intervals. Cytology, HPV testing, colposcopy, and pathology were performed before treatment and at 6-month follow-up after treatment to assess efficacy. The main outcome of this study was the regression of HSIL/CIN2 and the clearance of high-risk HPV (hrHPV) infection after ALA-PDT treatment. Clinicopathological characteristics were collected to analyze the factors affecting the effectiveness of ALA-PDT treatment for HSIL/CIN2. Results: Between the successful and failed lesion regression group, there was a significant difference in sleeping disorders (p < 0.05). Between the successful and failed hrHPV clearance group, no statistically significant factors were found. With sensitivity values of 0.556 and 0.778, respectively, multivariate analysis showed that current smoking and sleeping disorders were independent prognostics of failure in lesion regression after ALA-PDT treatment. Conclusions: Smoking and sleep disorders were independent risk factors for failure in HSIL/CIN2 regression following ALA-PDT, suggesting the need for careful consideration of ALA-PDT for patients with these conditions.
1. Introduction
Cervical cancer ranks as the fourth most common malignancy among women, with approximately 600,000 new cases and 340,000 related deaths occurring globally each year [1]. The persistent infection with high-risk human papillomavirus (hrHPV) is strongly associated with the development of cervical cancer. While most hrHPV infections are transient and can be cleared by the immune system, persistent infections can lead to cervical intraepithelial neoplasia (CIN) and ultimately invasive cancer. CIN is classified based on the depth of cervical epithelial involvement into CIN1, CIN2, and CIN3, with CIN2 and CIN3 considered high-grade squamous intraepithelial lesions (HSIL). Each grade of CIN exhibits distinct biological behaviors, and the risk of progression varies. At least 12% of CIN3 cases will advance to invasive cancer, while 18% of CIN2 cases progress to CIN3 and invasive cancer [2,3]. Notably, 11% of untreated CIN2 patients under the age of 30 progress within two years [4]. Thus, timely intervention for patients with cervical HSIL is critical to prevent the onset of cervical cancer. The preferred treatment for cervical HSIL is excisional therapy, such as cold-knife conization or loop electrosurgical excision (LEEP). However, these procedures can lead to postoperative complications, including cervical stenosis, adhesions, cervical endometriosis, and cervical insufficiency, which may increase the risk of adverse pregnancy outcomes [5]. Therefore, for women with cervical HSIL who wish to preserve their fertility, a non-invasive therapeutic intervention that reduces the progression rate of CIN2 to CIN3+ is highly desirable.
In recent years, photodynamic therapy (PDT) has been gradually applied in the treatment of a variety of benign and malignant diseases [6,7]. PDT mediated by 5-aminolevulinic acid (5-ALA) is a minimally invasive treatment for CIN. Different from ablation or excision, ALA-PDT uses photodynamic responses to selectively destroy lesions for therapeutic purposes. Local application of ALA-PDT has the advantages of less trauma, less adverse reactions, good selectivity, repeatability, and rapid recovery. The histological remission rate of HSIL/CIN2 treated with ALA-PDT ranges from 77.8% to 91% [8]. Despite these promising results, some patients with HSIL do not benefit from ALA-PDT and may even progress to invasive cancer. Administering conservative treatment without thorough consideration can exacerbate their condition and miss the optimal treatment window.
Therefore, analyzing the factors influencing ALA-PDT outcomes in cervical HSIL patients is essential to identify the most effective treatment strategies. In this study, we collected data on 13 clinicopathological characteristics and investigated their potential predictive ability for outcomes in cervical HSIL patients following ALA-PDT.
2. Materials and Methods
2.1. Study Design and Study Population
This was a retrospective study. From March 2019 to October 2023, women with hrHPV infection, a pathologic diagnosis of cervical HSIL/CIN2, complete clinical data, and who had received ALA-PDT at the Gynecology Department of Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, were selected. All participants completed a questionnaire administered by a specialist physician. The questionnaire covered demographics such as age, smoking and drinking habits, HPV vaccination status, sleep disorders, number of births and miscarriages, as well as details regarding HPV infection type, cervical cytology results, pathology findings, and laboratory tests such as platelet–lymphocyte ratio (PLR) and neutrophil–lymphocyte ratio (NLR). Those with incomplete questionnaire information and follow-up results were excluded.
2.2. HPV Testing and Cytological Test
HPV genotyping was performed through the flow-through hybridization-based 21 HPV GenoArray Diagnostic Kit (Hybribio Ltd., Chaozhou, China) to identify and stratify HPV infection into the 15 high-risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68) and six low-risk types (6, 11, 42, 43, 44, and 81). We classified HPV infections into the following two categories: HPV16/18 infections and non-HPV16/18 infections. Additionally, we differentiated between multiple-type HPV infections and single-type HPV infections. Cytological tests were performed using liquid-based cytology (ThinPrep cytological test, TCT). The results were categorized as negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), HSIL, atypical squamous cells that could not exclude HSIL, and cervical cancer.
2.3. Photodynamic Therapy
To prepare the 20% ALA mixture, 354 mg of 5-ALA powder (Fudan Zhangjiang Bio-Pharm Co., Ltd., Shanghai, China) was combined with 1.5 mL of thermogel (stored at 4 °C). Sterile cotton pieces soaked in the ALA mixture were applied to the cervix and incubated for four hours in the dark. Subsequently, light irradiation at 635 nm and a dose of 100 J/cm2 (LD600-C; Wuhan Yage Photo-Electronic Co., Ltd., Wuhan, China) was applied to the cervical surface and the endocervical canal for 30 min respectively. This treatment regimen was repeated six times at intervals of 7–14 days.
2.4. Follow-Up and Effect Evaluation
The primary outcomes measured were the regression of HSIL/CIN2 lesions and the clearance of hrHPV infection at the 6-month follow-up after ALA-PDT treatment. The specific grouping criteria were as follows:
- Lesion: The Success Group was defined as regression of HSIL/CIN2, indicated by either a negative pathological diagnosis or a reduction in histological severity compared to the initial state after ALA-PDT treatment. The Failed Group was defined as persistence of HSIL/CIN2 (no change in histological diagnosis) or progression to CIN3+ at follow-up.
- hrHPV: The Success Group was defined as conversion from baseline hrHPV-positive to hrHPV-negative at follow-up. The Failed Group was defined as hrHPV remaining positive at follow-up compared to the baseline.
2.5. Statistical Analysis
The collected data were analyzed using IBM SPSS software (Version 26.0, SPSS Inc., Chicago, IL, USA). Chi-square, Fisher’s exact, and t tests were conducted to evaluate the difference in the incidence of different outcome groups, respectively. Univariate and multivariate analyses were utilized to find independent predictive factors related to the outcome of HSIL/CIN2 patients undergoing ALA-PDT.
2.6. Ethical Considerations
All procedures adhered to the ethical standards of the Institutional and National Research Committee as well as the 1964 Declaration of Helsinki and its subsequent amendments or comparable ethical standards. Informed consent was obtained from all participants included in the study. The study received approval from the Ethics Committee of Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine (Committee’s reference number KY2021-248-B).
3. Results
We enrolled 69 eligible patients with cervical HSIL/CIN2 who received ALA-PDT into this study and gathered 13 clinicopathological characteristics for analysis.
3.1. Analysis of Factors Influencing the Effect of ALA-PDT on HSIL/CIN2 Regression
Among the 69 patients, 60 had experienced histologic regression following ALA-PDT at the 6-month follow-up.
As shown in Table 1, the regression of HSIL/CIN2 was significantly more challenging in patients with sleep disorders compared to those without (65.0% vs. 95.9%, p = 0.002). Additionally, patients who were current smokers appeared to have a lower lesion regression rate compared to non-smokers (70.6% vs. 92.3%, p = 0.058). There was no significant difference between the two groups in terms of age, drinking history, HPV vaccination, history of childbirth or abortion, PLR, NLR, multiple HPV type infections, HPV16/18 infection, and TCT results (p > 0.05). Additionally, ALA-PDT combined with CO2 lasers did not show a significantly different influence on the outcome compared to ALA-PDT alone (p = 0.357).
3.2. Analysis of Factors Influencing the Effect of ALA-PDT on hrHPV Clearance
Among the 69 patients, 44 achieved successful clearance of hrHPV, while 25 had persistent hrHPV infection at the 6-month follow-up. As shown in Table 2, current smoking was associated with a lower hrHPV clearance rate, but this difference was not statistically significant (p = 0.099). Additionally, results showed no statistically significant differences between the two groups for the other 12 clinicopathological characteristics.
3.3. Univariate and Multivariate Regression Analyses of Factors Influencing the Efficacy of ALA-PDT
We further conducted univariate and multivariate regression analyses to identify independent prognostic factors for the efficacy of ALA-PDT in treating HSIL/CIN2. We employed a stepwise multiple linear regression model to analyze variables with a significance level of p < 0.05 from the univariate analysis. As shown in Table 3, first, univariate regression analysis was conducted, revealing associations between current smoking, sleep disorders, and lesion efficacy (p < 0.05). Subsequent multivariate regression analysis further indicated that both factors are independent risk factors for poorer histological prognosis (p = 0.046 and p = 0.039, respectively). Current smoking was strongly associated with a lack of lesion regression, with sensitivity and specificity of 0.556 and 0.800, respectively. Similarly, patients with sleep disorders showed a higher risk of a lack of lesion regression compared to those without sleep disorders, with sensitivity and specificity of 0.778 and 0.783, respectively. For the hrHPV clearance, the univariate analysis showed no statistically significant clinicopathological characteristics (Table 4).
4. Discussion
The application of HPV vaccines, regular screening, and timely treatment of cervical precancerous lesions are effective preventive measures for cervical cancer. Untreated HSIL/CIN2 patients have a probability of developing cervical cancer [4]. Studies indicate that the majority of patients with cervical HSIL benefit from ALA-PDT, although a small number may not respond effectively [8,9]. Therefore, evaluating factors influencing ALA-PDT efficacy in cervical HSIL patients can aid in selecting more appropriate treatments. In this study, 13 clinicopathological variables were analyzed.
Smoking has been extensively studied for its association with various diseases. Reports have shown that smoking can cause DNA strand breaks, promote viral amplification in cervical cells infected with hrHPV, and enhance the expression of HPV E6 and E7 proteins [10,11]. A meta-analysis on Japanese women demonstrated that smoking was strongly associated with cervical cancer [10]. Reports also indicate that smoking increases the risk of recurrence of genital warts and HSIL [11]. Building on this, our analysis identified current smoking as an independent risk factor for failure in lesion regression following ALA-PDT. However, current smoking did not significantly affect hrHPV clearance in HSIL/CIN2 patients after ALA-PDT. Further studies with larger sample sizes and longer follow-up periods are warranted to validate these findings.
Numerous studies have demonstrated a connection between sleep and HPV infection. Short sleep durations may increase HPV infection likelihood [12]. Enhancement of sleep quality during HPV infection is assumed to feedback to the immune system to promote host defense [13]. In particular, slow-wave sleep can support immune system recovery [14]. Further understanding of the casual relationship between sleep deprivation and immune deregulation would help to identify individuals at risk of disease and to prevent adverse health outcomes [15]. However, another study found that the quality of sleep had no bearing on HPV infection [16]. The results of this study indicated that sleep significantly influenced lesion regression following ALA-PDT but did not affect hrHPV clearance. Sleep disorders were identified as an independent risk factor for poorer lesion outcomes in HSIL/CIN2 patients treated with ALA-PDT. These findings underscore that HSIL/CIN2 patients with better sleep quality may derive greater benefit from ALA-PDT.
Our previous studies proved that age was a risk factor for ALA-PDT, with the >50 age group showing a higher lesion progression rate and lower HPV remission rate than the <50 age group [17]. However, age did not affect the outcomes of ALA-PDT in patients with HSIL/CIN2 in this study. This may be attributed to the fact that the majority of patients were younger than 50 years old (66/69, 95.65%), reflecting the preference of young women with fertility concerns opting for ALA-PDT.
Drinking habits and HPV vaccination are known clinical factors that influence HPV infection [18,19,20,21]. A history of childbirth and abortion is also believed to impact vaginal health. We were interested in how these factors might affect the efficacy of ALA-PDT in HSIL/CIN2 patients. Our results showed no significant difference between the groups that achieved success and those that did not in terms of drinking habits, HPV vaccination status, or history of childbirth or abortion. However, further analysis with larger or multi-center sample sizes is needed to derive conclusive findings. Additionally, stratified analysis based on specific childbirth or abortion histories and types of HPV vaccines warrants further research.
HPV testing and the TCT are common laboratory indicators for cervical lesions. A previous study demonstrated that HPV 16/18 positive cases can benefit most from ALA-PDT, and the HPV clearance rate in patients with multiple-type HPV infection was significantly lower than that in patients with single-type HPV infection [22]. The TCT has some degree of cervical lesion presentation and CIN/HSIL diagnostic value; however, in this study, HPV16/18 infection, multiple-type HPV infections, and TCT results were not found to be associated with the outcome of ALA-PDT treatment for HSIL/CIN2, which may be due to the variations in methods or patient populations. The NLR and PLR of blood are indicators of not only systemic inflammation but also different malignancies [23]. One study reported the NLR is an independent prognostic factor for relapse-free survival following surgical resection in CIN patients [24]. Furthermore, preoperative PLR levels could be a marker for predicting recurrence/residual disease of HSIL after LEEP [24]. We found that the NLR and PLR did not affect the outcome of ALA-PDT treatment for HSIL.
ALA-PDT combined with CO2 laser assistance is being explored to enhance its effectiveness and improve patient tolerance. The CO2 laser itself has therapeutic benefits. Previous clinical studies have shown improved lesion response when a CO2 laser is used before PDT compared to ALA-PDT or laser treatment alone [25,26]. However, this study revealed that there was no significant difference between the ALA-PDT+ CO2 laser group and the ALA-PDT group.
These results can inform ALA-PDT treatment for HSIL/CIN2 patients in the future. For patients who smoke or are in a smoking environment for a long time, it is necessary to quit smoking or consciously stay away from the smoking environment before ALA-PDT treatment and maintain this until the lesions have regressed. For patients with sleep disorders, they should be helped to find the cause, through symptomatic and etiological treatment, to improve their quality of sleep. These steps require the joint efforts of patients, families, and doctors. Having regular telephone or home follow-up appointments and the timely monitoring of the lifestyle behaviors of study participants will contribute to the rigor of future clinical studies.
The major deficiencies of this study were the small, single-center sample and short follow-up, which may have caused bias. Furthermore, analysis of the clinicopathological characteristics was not detailed enough, and hierarchical analysis may help evaluate the influences of characteristics more comprehensively.
5. Conclusions
Overall, we examined the relationship between 13 clinicopathological characteristics and the impact of ALA-PDT on HSIL/CIN2 patients. Our findings indicated that smoking and sleep disorders are independent risk factors for failure in lesion regression, while age, NLR, PLR, drinking, HPV vaccine, HPV infection type, TCT results, history of giving birth and abortion, and CO2 laser combination therapy have no effect on lesion regression. No factors affecting hrHPV clearance were found. We suggest that careful consideration is given when evaluating ALA-PDT for patients who smoke and those with sleep disorders. To make informed treatment decisions for HSIL patients, further trials with larger sample sizes and longer follow-up periods are necessary to confirm these findings and explore additional prognostic factors for ALA-PDT.
Author Contributions
Y.W.: writing—original draft, writing—review and editing, software, and investigation; J.N.: Writing—original draft, software, and methodology; L.G.: investigation and data curation; Z.H.: investigation and data curation; Z.B.: supervision, project administration, and methodology; L.Q.: writing—review and editing, supervision, resources, project administration, methodology, data curation, and conceptualization. All authors have read and agreed to the published version of the manuscript.
Funding
This work was financially supported by the Clinical Research Innovation and Cultivation Fund of Renji Hospital, Shanghai Jiao Tong University School of Medicine (RJPY-DZX-002); the Medical and Engineering Cross Research Fund of “Star of Jiao Tong University” Program of Shanghai Jiao Tong University (YG2023ZD08); the National Natural Science Foundation of China (82072865); the Health and Family Planning Scientific Research Project of Pudong New Area Health Commission (PW2022D-03); the Natural Science Foundation of Shanghai (21ZR1438600); and the Shanghai Rising-Star Program (23QC1400100).
Institutional Review Board Statement
The study received approval from the Ethics Committee of Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine (Committee’s reference number KY2021-248-B).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding authors.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Ostör, A.G. Natural history of cervical intraepithelial neoplasia: A critical review. Int. J. Gynecol. Pathol. 1993, 12, 186–192. [Google Scholar] [CrossRef] [PubMed]
- Tainio, K.; Athanasiou, A.; Tikkinen, K.A.O.; Aaltonen, R.; Cárdenas, J.; Hernándes Glazer-Livson, S.; Jakobsson, M.; Joronen, K.; Kiviharju, M.; Louvanto, K.; et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: Systematic review and meta-analysis. BMJ 2018, 360, k499. [Google Scholar] [CrossRef] [PubMed]
- Louvanto, K.; Aro, K.; Nedjai, B.; Bützow, R.; Jakobsson, M.; Kalliala, I.; Dillner, J.; Nieminen, P.; Lorincz, A. Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia. Clin. Infect. Dis. 2020, 70, 2582–2590. [Google Scholar] [CrossRef] [PubMed]
- Cho, A.; Park, S.; Park, S.; Kang, H.S.; Shim, S.S.; Park, C.M.; Kim, S.Y. Hemoperitoneum: A complication of loop electrosurgical excision procedure. Obstet. Gynecol. Sci. 2019, 62, 138–141. [Google Scholar] [CrossRef]
- Pallavi, P.; Girigoswami, K.; Gowtham, P.; Harini, K.; Thirumalai, A.; Girigoswami, A. Rhodamine 6G in Oxidized Sodium Alginate Polymeric Hydrogel for Photodynamically Inactivating Cancer Cells. Curr. Pharm. Des. 2024. [Google Scholar] [CrossRef] [PubMed]
- Pallavi, P.; Harini, K.; Elboughdiri, N.; Gowtham, P.; Girigoswami, K.; Girigoswami, A. Infections associated with SARS-CoV-2 exploited via nanoformulated photodynamic therapy. ADMET DMPK 2023, 11, 513–531. [Google Scholar] [CrossRef]
- Qiu, L.; Li, J.; Chen, F.; Wang, Y.; Wang, Y.; Wang, X.; Lv, Q.; Li, C.; Li, M.; Yang, Q.; et al. Chinese expert consensus on the clinical applications of aminolevulinic acid-based photodynamic therapy in female lower genital tract diseases (2022). Photodiagn. Photodyn. Ther. 2022, 39, 102993. [Google Scholar] [CrossRef]
- Ozog, D.M.; Rkein, A.M.; Fabi, S.G.; Gold, M.H.; Goldman, M.P.; Lowe, N.J.; Martin, G.M.; Munavalli, G.S. Photodynamic Therapy: A Clinical Consensus Guide. Dermatol. Surg. 2016, 42, 804–827. [Google Scholar] [CrossRef]
- Sugawara, Y.; Tsuji, I.; Mizoue, T.; Inoue, M.; Sawada, N.; Matsuo, K.; Ito, H.; Naito, M.; Nagata, C.; Kitamura, Y.; et al. Cigarette smoking and cervical cancer risk: An evaluation based on a systematic review and meta-analysis among Japanese women. Jpn. J. Clin. Oncol. 2019, 49, 77–86. [Google Scholar] [CrossRef]
- Kaderli, R.; Schnüriger, B.; Brügger, L.E. The impact of smoking on HPV infection and the development of anogenital warts. Int. J. Color. Dis. 2014, 29, 899–908. [Google Scholar] [CrossRef]
- Hu, H.; Wu, Y.; Zhao, M.; Liu, J.; Xie, P. Sleep duration time and human papillomavirus infection risk: The U-shaped relationship revealed by NHANES data. PLoS ONE 2024, 19, e0301212. [Google Scholar] [CrossRef] [PubMed]
- Besedovsky, L.; Lange, T.; Haack, M. The Sleep-Immune Crosstalk in Health and Disease. Physiol. Rev. 2019, 99, 1325–1380. [Google Scholar] [CrossRef] [PubMed]
- Majde, J.A.; Krueger, J.M. Links between the innate immune system and sleep. J. Allergy Clin. Immunol. 2005, 116, 1188–1198. [Google Scholar] [CrossRef] [PubMed]
- Garbarino, S.; Lanteri, P.; Bragazzi, N.L.; Magnavita, N.; Scoditti, E. Role of sleep deprivation in immune-related disease risk and outcomes. Commun. Biol. 2021, 4, 1304. [Google Scholar] [CrossRef]
- Li, Y.; Liu, M.; Huang, P.; Wang, W.; Jiang, Y.; Yang, Z.; Wang, A. The lifestyle factors of physical activity and diet balance associated with HPV infection in China: The cross-sectional study. Front. Oncol. 2022, 12, 1043937. [Google Scholar] [CrossRef]
- Gu, L.; Cheng, M.; Hong, Z.; Di, W.; Qiu, L. The effect of local photodynamic therapy with 5-aminolevulinic acid for the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: A retrospective study. Photodiagn. Photodyn. Ther. 2021, 33, 102172. [Google Scholar] [CrossRef]
- De Sanjosé, S.; Brotons, M.; Pavón, M.A. The natural history of human papillomavirus infection. Best. Pract. Res. Clin. Obstet. Gynaecol. 2018, 47, 2–13. [Google Scholar] [CrossRef]
- Weiderpass, E.; Ye, W.; Tamimi, R.; Trichopolous, D.; Nyren, O.; Vainio, H.; Adami, H.O. Alcoholism and risk for cancer of the cervix uteri, vagina, and vulva. Cancer Epidemiol. Biomark. Prev. 2001, 10, 899–901. [Google Scholar]
- Wong, M.C.S.; Vlantis, A.C.; Liang, M.; Wong, P.Y.; Ho, W.C.S.; Boon, S.S.; Leung, C.; Chan, P.K.S.; Chen, Z. Persistence and clearance of oral human papillomavirus infections: A prospective population-based cohort study. J. Med. Virol. 2020, 92, 3807–3814. [Google Scholar] [CrossRef]
- Oyouni, A.A.A. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J. Infect. Public Health 2023, 16, 626–631. [Google Scholar] [CrossRef] [PubMed]
- Cang, W.; Gu, L.; Hong, Z.; Wu, A.; Di, W.; Qiu, L. Effectiveness of photodynamic therapy with 5-aminolevulinic acid on HPV clearance in women without cervical lesions. Photodiagn. Photodyn. Ther. 2021, 34, 102293. [Google Scholar] [CrossRef] [PubMed]
- Fang, T.; Wang, Y.; Yin, X.; Zhai, Z.; Zhang, Y.; Yang, Y.; You, Q.; Li, Z.; Ma, Y.; Li, C.; et al. Diagnostic Sensitivity of NLR and PLR in Early Diagnosis of Gastric Cancer. J. Immunol. Res. 2020, 2020, 9146042. [Google Scholar] [CrossRef] [PubMed]
- Chun, S.; Shin, K.; Kim, K.H.; Kim, H.Y.; Eo, W.; Lee, J.Y.; Namkung, J.; Kwon, S.H.; Koh, S.B.; Kim, H.B. The Neutrophil-Lymphocyte Ratio Predicts Recurrence of Cervical Intraepithelial Neoplasia. J. Cancer 2017, 8, 2205–2211. [Google Scholar] [CrossRef]
- Cai, H.; Wang, Y.X.; Zheng, J.C.; Sun, P.; Yang, Z.Y.; Li, Y.L.; Liu, X.Y.; Li, Q.; Liu, W. Photodynamic therapy in combination with CO2 laser for the treatment of Bowen’s disease. Lasers Med. Sci. 2015, 30, 1505–1510. [Google Scholar] [CrossRef]
- Lippert, J.; Smucler, R.; Vlk, M. Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatol. Surg. 2013, 39, 1202–1208. [Google Scholar] [CrossRef]
Table 1.
Analysis of factors influencing the effect of ALA-PDT on HSIL/CIN2 regression.
| Characteristics | Sum (n = 69) | Success in Lesion Regression (n = 60) | Failure in Lesion Regression (n = 9) | χ2/t | p/p′/ Fisher |
|---|---|---|---|---|---|
| Age [x ± s, years] | 30.55 ± 7.25 | 30.63 ± 7.61 | 30.00 ± 4.44 | 0.243 | 0.809 |
| NLR [x ± s] | 2.14 ± 0.85 | 2.13 ± 0.89 | 2.20 ± 0.53 | −0.207 | 0.837 |
| PLR [x ± s] | 128.75 ± 40.18 | 127.34 ± 40.37 | 138.18 ± 39.90 | −0.752 | 0.455 |
| current smoking [n, (%)] | |||||
| not | 52 (75.4%) | 48 (92.3%) | 4 (7.7%) | 3.586 | 0.058 |
| yes | 17 (24.6%) | 12 (70.6%) | 5 (29.4%) | ||
| drinking history [n, (%)] | |||||
| not | 58 (84.1%) | 52 (89.7%) | 6 (10.3%) | 1.082 | 0.298 |
| yes | 11 (15.9%) | 8 (72.7%) | 3 (27.3%) | ||
| sleeping disorders [n, (%)] | |||||
| not | 49 (71%) | 47 (95.9%) | 2 (4.1%) | 9.400 | 0.002 |
| yes | 20 (29%) | 13 (65.0%) | 7 (35.0%) | ||
| HPV vaccination [n, (%)] | |||||
| not | 54 (78.3%) | 45 (83.3%) | 9 (16.7%) | 1.593 | 0.207 |
| yes | 15 (21.7%) | 15 (100.0%) | 0 (0.0%) | ||
| HPV16/18 infection [n, (%)] | |||||
| not | 25 (36.2%) | 22 (88.0%) | 3 (12.0%) | 0.000 | 1.000 |
| yes | 44 (63.8%) | 38 (86.4%) | 6 (13.6%) | ||
| multiple types of HPV infection [n, (%)] | |||||
| not | 48 (69.6%) | 43 (89.6%) | 5 (10.4%) | 0.349 | 0.554 |
| yes | 21 (30.4%) | 17 (81.0%) | 4 (19.0%) | ||
| Thinpred cytologic test [n, (%)] | |||||
| ≤ASCUS | 40 (58%) | 36 (90.0%) | 4 (10.0%) | 0.270 | 0.603 |
| ≥LSIL | 29 (42%) | 24 (82.8%) | 5 (17.2%) | ||
| history of giving birth [n, (%)] | |||||
| not | 50 (72.5%) | 43 (86.0%) | 7 (14.0%) | 0.000 | 1.000 |
| yes | 19 (27.5%) | 17 (89.5%) | 2 (10.5%) | ||
| abortion history [n, (%)] | |||||
| not | 48 (69.6%) | 42 (87.5%) | 6 (12.5%) | 0.000 | 1.000 |
| yes | 21 (30.4%) | 18 (85.7%) | 3 (14.3%) | ||
| combined with CO2 laser [n, (%)] | |||||
| not | 44 (63.8%) | 40 (90.9%) | 4 (9.1%) | 0.849 | 0.357 |
| yes | 25 (36.2%) | 20 (80.0%) | 5 (20.0%) | ||
NLR: neutrophil–lymphocyte ratio; PLR: platelets–lymphocyte ratio. Current smoking: a regular active smoker or exposure to environmental tobacco smoke. Non-current smokers had quit or never smoked regularly. Drinking history: participants engaged in drinking (≥14 drinks/wk for women) for a 30-day consecutive period and ≥2 heavy drinking days (defined as ≥4 drinks/d for women) in the 90 days preceding or during ALA-PDT. Sleep disorders: according to the International Classification of Sleep Disorders-3 (ICSD-3), insomnia disorders, sleep-related breathing disorders, central disorders of hypersomnolence, circadian rhythm sleep–wake disorders, sleep-related movement disorders, parasomnias, and other sleep disorders were defined as sleep disorders. HPV vaccination means a patient had received three shots of HPV vaccine before ALA-PDT, no matter whether the bivalent, quadrivalent, or nine-valent vaccine.
Table 2.
Analysis of factors influencing the effect of ALA-PDT on hrHPV clearance.
| Characteristics | Sum (n = 69) | Success in hrHPV Clearance (n = 44) | Failure in hrHPV Clearance (n = 25) | χ2/t | p/p′/ Fisher |
|---|---|---|---|---|---|
| Age [x ± s, years] | 30.55 ± 7.25 | 30.77 ± 7.52 | 30.16 ± 6.89 | 0.335 | 0.739 |
| NLR [x ± s] | 2.14 ± 0.85 | 2.14 ± 0.84 | 2.15 ± 0.88 | −0.083 | 0.934 |
| PLR [x ± s] | 128.75 ± 40.18 | 124.96 ± 40.93 | 135.42 ± 38.75 | −1.040 | 0.302 |
| current smoking [n, (%)] | |||||
| not | 52 (75.4%) | 36 (69.2%) | 16 (30.8%) | 2.726 | 0.099 |
| yes | 17 (24.6%) | 8 (47.1%) | 9 (52.9%) | ||
| drinking history [n, (%)] | |||||
| not | 58 (84.1%) | 39 (67.2%) | 19 (32.8%) | 1.074 | 0.300 |
| yes | 11 (15.9%) | 5 (45.5%) | 6 (54.5%) | ||
| sleeping disorders [n, (%)] | |||||
| not | 49 (71.0%) | 34 (69.4%) | 15 (30.6%) | 2.311 | 0.128 |
| yes | 20 (29.0%) | 10 (50.0%) | 10 (50.0%) | ||
| HPV vaccination [n, (%)] | |||||
| not | 54 (78.3%) | 34 (63.0%) | 20 (37.0%) | 0.070 | 0.792 |
| yes | 15 (21.7%) | 10 (66.7%) | 5 (33.3%) | ||
| HPV16/18 infection [n, (%)] | |||||
| not | 25 (36.2%) | 19 (76%) | 6 (24%) | 2.539 | 0.111 |
| yes | 44 (63.8%) | 25 (58.6%) | 19 (43.2%) | ||
| multiple types of HPV infection [n, (%)] | |||||
| not | 48 (69.6%) | 32 (66.7%) | 16 (33.3%) | 0.574 | 0.449 |
| yes | 21 (30.4%) | 12 (57.1%) | 9 (42.9%) | ||
| Thinpred cytologic test [n, (%)] | |||||
| ≤ASCUS | 40 (58.0%) | 25 (62.5%) | 15 (37.5%) | 0.066 | 0.797 |
| ≥LSIL | 29 (42.0%) | 19 (65.5%) | 10 (34.5%) | ||
| history of giving birth [n, (%)] | |||||
| not | 50 (72.5%) | 33 (66.0%) | 17 (34.0%) | 0.391 | 0.532 |
| yes | 19 (27.5%) | 11 (57.9%) | 8 (42.1%) | ||
| abortion history [n, (%)] | |||||
| not | 48 (69.6%) | 32 (66.7%) | 16 (33.3%) | 0.574 | 0.449 |
| yes | 21 (30.4%) | 12 (57.1%) | 9 (42.9%) | ||
| combined with CO2 laser [n, (%)] | |||||
| not | 44 (63.8%) | 28 (63.6%) | 16 (36.4%) | 0.001 | 0.976 |
| yes | 25 (36.2%) | 16 (64.0%) | 9 (36.0%) | ||
Table 3.
Univariate and multivariate regression analysis of factors influencing the effect of ALA-PDT on HSIL/CIN2 regression.
Table 3.
Univariate and multivariate regression analysis of factors influencing the effect of ALA-PDT on HSIL/CIN2 regression.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| Characteristics | p | OR (95% CI) | p | OR (95% CI) |
| age | 0.806 | 0.987 (0.891–1.093) | ||
| NLR | 0.834 | 1.089 (0.489–2.427) | ||
| PLR | 0.451 | 1.006 (0.990–1.023) | ||
| current smoking | 0.031 | 5.000 (1.162–21.509) | 0.046 | 5352.87 (1.15–2.48 × 107) |
| drinking history | 0.142 | 3.250 (0.674–15.671) | ||
| sleeping disorders | 0.003 | 12.654 (2.341–68.387) | 0.039 | 5466.59 (1.58–1.90 × 107) |
| HPV vaccination | 0.998 | 0.000 (0.000–0.000) | ||
| HPV16/18 infection | 0.846 | 1.158 (0.263–5.097) | ||
| multiple types of HPV infection | 0.334 | 2.024 (0.484–8.453) | ||
| TCT | 0.383 | 1.875 (0.457–7.700) | ||
| history of giving birth | 0.703 | 0.723 (0.136–3.834) | ||
| abortion history | 0.840 | 1.167 (0.262–5.186) | ||
| combined with CO2 laser | 0.206 | 2.500 (0.604–10.344) | ||
Table 4.
Univariate regression analysis of factors influencing the effect of ALA-PDT on hrHPV clearance.
Table 4.
Univariate regression analysis of factors influencing the effect of ALA-PDT on hrHPV clearance.
| Univariate Analysis | ||
|---|---|---|
| Characteristics | p | OR (95% CI) |
| age | 0.734 | 0.988 (0.922–1.059) |
| NLR | 0.933 | 1.025 (0.575–1.827) |
| PLR | 0.301 | 1.007 (0.994–1.019) |
| current smoking | 0.104 | 2.531 (0.826–7.756) |
| drinking history | 0.177 | 2.463 (0.666–9.105) |
| sleeping disorders | 0.133 | 2.267 (0.780–6.585) |
| HPV vaccination | 0.792 | 0.850 (0.254–2.843) |
| HPV16/18 infection included | 0.116 | 2.407 (0.805–7.191) |
| multiple types of HPV infection | 0.450 | 1.500 (0.524–4.296) |
| TCT | 0.797 | 0.877 (0.323–2.380) |
| history of giving birth | 0.532 | 1.412 (0.478–4.168) |
| abortion history | 0.450 | 1.500 (0.524–4.296) |
| combined with CO2 laser | 0.976 | 0.984 (0.354–2.735) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Wei, Y.; Niu, J.; Gu, L.; Hong, Z.; Bao, Z.; Qiu, L. Effect of Clinicopathological Characteristics on the Outcomes of Topical 5-Aminolevulinic Acid Photodynamic Therapy in Patients with Cervical High-Grade Squamous Intraepithelial Lesions (HSIL/CIN2): A Retrospective Cohort Study. Biomedicines 2024, 12, 2255. https://doi.org/10.3390/biomedicines12102255
AMA Style
Wei Y, Niu J, Gu L, Hong Z, Bao Z, Qiu L. Effect of Clinicopathological Characteristics on the Outcomes of Topical 5-Aminolevulinic Acid Photodynamic Therapy in Patients with Cervical High-Grade Squamous Intraepithelial Lesions (HSIL/CIN2): A Retrospective Cohort Study. Biomedicines. 2024; 12(10):2255. https://doi.org/10.3390/biomedicines12102255
Chicago/Turabian StyleWei, Yingting, Jing Niu, Liying Gu, Zubei Hong, Zhouzhou Bao, and Lihua Qiu. 2024. "Effect of Clinicopathological Characteristics on the Outcomes of Topical 5-Aminolevulinic Acid Photodynamic Therapy in Patients with Cervical High-Grade Squamous Intraepithelial Lesions (HSIL/CIN2): A Retrospective Cohort Study" Biomedicines 12, no. 10: 2255. https://doi.org/10.3390/biomedicines12102255
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
